Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab

Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.